Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain

ClinicalTrials.gov ID: NCT02324270

Public ClinicalTrials.gov record NCT02324270. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-Blind, Multiple-Center, Placebo-Controlled Study Comparing the Safety and Efficacy of Generic Diclofenac Epolamine to Flector® Patch in the Treatment of Acute Pain Due to Minor Ankle Sprain

Study identification

NCT ID
NCT02324270
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Actavis Inc.
Industry
Enrollment
658 participants

Conditions and interventions

Conditions

Interventions

  • Diclofenac epolamine Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2014
Primary completion
Nov 30, 2014
Completion
Nov 30, 2014
Last update posted
Jun 23, 2020

2014

United States locations

U.S. sites
31
U.S. states
16
U.S. cities
29
Facility City State ZIP Site status
Site 21 Birmingham Alabama 35209
Site 24 Goodyear Arizona 85395
Site 08 Carlsbad California 92008
Site 05 Ventura California 93003
Site 16 Clinton Connecticut 84105
Site 03 Riverton Connecticut 84065
Site 11 Daytona Beach Florida 32117
Site 09 DeLand Florida 32720
Site 14 Miami Florida 33144
Site 07 Miami Florida 33155
Site 13 Miami Florida 33155
Site 02 West Palm Beach Florida 33409
Site 26 Lexington Kentucky 40509
Site 12 Gretna Louisiana 70056
Site 23 Kalamazoo Michigan 85395
Site 41 Traverse City Michigan 49684
Site 10 Omaha Nebraska 32117
Site 29 Berlin New Jersey 08009
Site 18 Brooklyn New York 11201
Site 19 Cincinnati Ohio 45246
Site 30 Columbus Ohio 43214
Site 35 Oklahoma City Oklahoma 73112
Site 37 Downingtown Pennsylvania 19355
Site 27 State College Pennsylvania 16801
Site 15 Austin Texas 78756
04 El Paso Texas 93003
Site 34 Houston Texas 77089
Site 36 Lake Jackson Texas 77566
Site 22 San Antonio Texas 78218
Site 31 Danville Virginia 24541
Site 06 Newport News Virginia 23606

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02324270, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 23, 2020 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02324270 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →